Saturday, August 20, 2022
SCIENMAG: Latest Science and Health News
No Result
View All Result
  • Login
  • HOME PAGE
  • BIOLOGY
  • CHEMISTRY AND PHYSICS
  • MEDICINE
    • Cancer
    • Infectious Emerging Diseases
  • SPACE
  • TECHNOLOGY
  • CONTACT US
  • HOME PAGE
  • BIOLOGY
  • CHEMISTRY AND PHYSICS
  • MEDICINE
    • Cancer
    • Infectious Emerging Diseases
  • SPACE
  • TECHNOLOGY
  • CONTACT US
No Result
View All Result
Scienmag - Latest science news from science magazine
No Result
View All Result
Home SCIENCE NEWS Medicine & Health

MD Anderson and Enumeral enter into collaborative research and development agreement

January 11, 2016
in Medicine & Health
0
Share on FacebookShare on Twitter

The University of Texas MD Anderson Cancer Center today announced that it has entered into a collaborative research and development agreement with Enumeral Biomedical Holdings Inc.

Scientists from Enumeral and MD Anderson will collaborate on the discovery and development of novel monoclonal antibodies against specified targets in immuno-oncology, leveraging Enumeral's antibody discovery and patient-centric immune profiling platform and MD Anderson's pre-clinical and development expertise and infrastructure. Under the terms of the agreement, Enumeral and MD Anderson will share the costs of such research and development activities, and will each be granted the right to receive a percentage of the net income from product sales or any payments associated with licensing or otherwise partnering a program with a third party.

"This strategic collaboration leverages the considerable experience of MD Anderson in translational medicine and clinical oncology and Enumeral's core strengths of antibody discovery and patient-centric functional immune profiling," said Arthur H. Tinkelenberg, Ph.D., Enumeral's president and chief executive officer. "With our platform's ability to measure the effects of novel antibody candidates on human lymphocyte function in tumor biopsy samples from patients, and MD Anderson's deep expertise and infrastructure for pre-clinical and clinical oncology product development, we believe working with MD Anderson and their Oncology Research for Biologics and Immunotherapy Translation (ORBIT) team is an ideal way to accelerate the discovery and development of novel antibody therapies which may increase the rates of response and provide for more durable outcomes in the treatment of cancer."

ORBIT is a translational research platform of MD Anderson's Moon Shots Program, which aims to accelerate the conversion of scientific knowledge into clinical advances that reduce cancer deaths.

"With its team of industry-seasoned scientists embedded in a top-notch cancer center, ORBIT was launched to establish this type of collaboration," said Carlo Toniatti, M.D., Ph.D., executive director of ORBIT. "Successful development of novel anti-cancer antibodies requires faultless integration of drug development expertise, deep biological knowledge and clinical development capabilities. We are confident that through this collaboration we will accelerate the delivery of innovative and efficacious therapies to our patients."

###

Media Contact

Ron Gilmore
[email protected]
713-745-1898
@mdandersonnews

http://www.mdanderson.org

Share25Tweet16Share4ShareSendShare
  • Fig1_EcosystemReconstruction(Credit_HenrySharpe).png

    Global warming spawned the age of reptiles

    70 shares
    Share 28 Tweet 18
  • 60 million years of climate change drove the evolution and diversity of reptiles

    68 shares
    Share 27 Tweet 17
  • In wine, there’s health: Low levels of alcohol good for the brain

    67 shares
    Share 26 Tweet 17
  • New insights on how some individuals with obesity can lose weight – and keep it off

    70 shares
    Share 28 Tweet 18
  • UArizona Cancer Center receives highest NCI designation as Comprehensive Cancer Center

    68 shares
    Share 27 Tweet 17
  • Climate change may cause steeper wheat price spikes and economic inequality

    65 shares
    Share 26 Tweet 16
ADVERTISEMENT

About us

We bring you the latest science news from best research centers and universities around the world. Check our website.

Latest NEWS

Reinvigorating ‘lost cause’ exhausted T cells could improve cancer immunotherapy

Allison Institute announces formation of scientific advisory board

How quinine caused World War I (hyperbolic title alert) (video)

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 194 other subscribers

© 2022 Scienmag- Science Magazine: Latest Science News.

No Result
View All Result
  • HOME PAGE
  • BIOLOGY
  • CHEMISTRY AND PHYSICS
  • MEDICINE
    • Cancer
    • Infectious Emerging Diseases
  • SPACE
  • TECHNOLOGY
  • CONTACT US

© 2022 Scienmag- Science Magazine: Latest Science News.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In